Universitat de Lleida
    • English
    • català
    • español
  • English 
    • English
    • català
    • español
  • Login
Repositori Obert UdL
View Item 
  •   Home
  • Recerca
  • Ciències Mèdiques Bàsiques
  • Articles publicats (Ciències Mèdiques Bàsiques)
  • View Item
  •   Home
  • Recerca
  • Ciències Mèdiques Bàsiques
  • Articles publicats (Ciències Mèdiques Bàsiques)
  • View Item
JavaScript is disabled for your browser. Some features of this site may not work without it.

Oncogenic role of the ubiquitin ligase subunit Skp2 in human breast cancer

Thumbnail
View/Open
009173.pdf (5.864Mb)
Issue date
2002
Author
Signoretti, Sabina
Di Marcotullio, Lucia
Richardson, Andrea
Ramaswamy, Sridhar
Isaac, Beth
Rué i Monné, Montserrat
Monti, Franco
Loda, Massimo
Pagano, Michele
Suggested citation
Signoretti, Sabina; Di Marcotullio, Lucia; Richardson, Andrea; Ramaswamy, Sridhar; Isaac, Beth; Rué i Monné, Montserrat; ... Pagano, Michele. (2002) . Oncogenic role of the ubiquitin ligase subunit Skp2 in human breast cancer. Journal of Clinical Investigation, 2002, vol.110, núm. 5, p. 633-641. https://doi.org/10.1172/JCI15795.
Impact


Web of Science logo    citations in Web of Science

Scopus logo    citations in Scopus

Google Scholar logo  Google Scholar
Share
Export to Mendeley
Metadata
Show full item record
Abstract
Estrogen receptor (ER) expression and Her-2 amplification define specific subsets of breast tumors for which specific therapies exist. The S-phase kinase-associated protein Skp2 is required for the ubiquitin-mediated degradation of the cdk-inhibitor p27 and is a bona fide proto-oncoprotein. Using microarray analysis and immunohistochemistry, we determined that higher levels of Skp2 are present more frequently in ER-negative tumors than in ER-positive cases. Interestingly, the subset of ER-negative breast carcinomas overexpressing Skp2 are also characterized by high tumor grade, negativity for Her-2, basal-like phenotype, high expression of certain cell cycle regulatory genes, and low levels of p27 protein. We also found that Skp2 expression is cell adhesion-dependent in normal human mammary epithelial cells but not in breast cancer cells and that an inhibition of Skp2 induces a decrease of adhesion-independent growth in both ER-positive and ER-negative cancer cells. Finally, forced expression of Skp2 abolished effects of antiestrogens, suggesting that deregulated Skp2 expression might play a role in the development of resistance to antiestrogens. We conclude that Skp2 has oncogenic potential in breast epithelial cells and is overexpressed in a subset of breast carcinomas (ER- and Her-2 negative) for which Skp2 inhibitors may represent a valid therapeutic option.
URI
http://hdl.handle.net/10459.1/56695
DOI
https://doi.org/10.1172/JCI15795
Is part of
Journal of Clinical Investigation, 2002, vol.110, núm. 5, p. 633-641
European research projects
Collections
  • Articles publicats (Ciències Mèdiques Bàsiques) [581]

Contact Us | Send Feedback | Legal Notice
© 2023 BiD. Universitat de Lleida
Metadata subjected to 
 

 

Browse

All of the repositoryCommunities & CollectionsBy Issue DateAuthorsTitlesSubjectsThis CollectionBy Issue DateAuthorsTitlesSubjects

Statistics

View Usage Statistics

D'interès

Política institucional d'accés obertDiposita les teves publicacionsDiposita dades de recercaSuport a la recerca

Contact Us | Send Feedback | Legal Notice
© 2023 BiD. Universitat de Lleida
Metadata subjected to